The diagnostic value of staging laparoscopy in gallbladder cancer: a nationwide cohort study.


Journal

World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544

Informations de publication

Date de publication:
14 Jan 2023
Historique:
received: 28 09 2022
accepted: 17 12 2022
entrez: 14 1 2023
pubmed: 15 1 2023
medline: 18 1 2023
Statut: epublish

Résumé

Disseminated disease (DD) is often found at (re-)exploration in gallbladder cancer (GBC) patients. We aimed to assess the yield of staging laparoscopy (SL) and identify predictors for DD. This retrospective study included patients from all Dutch academic centres with primary GBC (pGBC) and incidentally diagnosed GBC (iGBC) planned for (re-)resection. The yield of SL was determined. In iGBC, predictive factors for DD were assessed. In total, 290 patients were included. Of 183 included pGBC patients, 143 underwent laparotomy without SL, and 42 (29%) showed DD perioperatively. SL, conducted in 40 patients, identified DD in eight. DD was found in nine of 32 patients who underwent laparotomy after SL. Of 107 included iGBC patients, 100 underwent laparotomy without SL, and 19 showed DD perioperatively. SL, conducted in seven patients, identified DD in one. Cholecystitis (OR = 4.25; 95% CI 1.51-11.91) and primary R1/R2 resection (OR = 3.94; 95% CI 1.39-11.19) were independent predictive factors for DD. In pGBC patients, SL may identify DD in up to 20% of patients and should be part of standard management. In iGBC patients, SL is indicated after primary resection for cholecystitis and after initial R1/R2 resection due to the association of these factors with DD.

Sections du résumé

BACKGROUND BACKGROUND
Disseminated disease (DD) is often found at (re-)exploration in gallbladder cancer (GBC) patients. We aimed to assess the yield of staging laparoscopy (SL) and identify predictors for DD.
METHODS METHODS
This retrospective study included patients from all Dutch academic centres with primary GBC (pGBC) and incidentally diagnosed GBC (iGBC) planned for (re-)resection. The yield of SL was determined. In iGBC, predictive factors for DD were assessed.
RESULTS RESULTS
In total, 290 patients were included. Of 183 included pGBC patients, 143 underwent laparotomy without SL, and 42 (29%) showed DD perioperatively. SL, conducted in 40 patients, identified DD in eight. DD was found in nine of 32 patients who underwent laparotomy after SL. Of 107 included iGBC patients, 100 underwent laparotomy without SL, and 19 showed DD perioperatively. SL, conducted in seven patients, identified DD in one. Cholecystitis (OR = 4.25; 95% CI 1.51-11.91) and primary R1/R2 resection (OR = 3.94; 95% CI 1.39-11.19) were independent predictive factors for DD.
CONCLUSIONS CONCLUSIONS
In pGBC patients, SL may identify DD in up to 20% of patients and should be part of standard management. In iGBC patients, SL is indicated after primary resection for cholecystitis and after initial R1/R2 resection due to the association of these factors with DD.

Identifiants

pubmed: 36641472
doi: 10.1186/s12957-022-02880-z
pii: 10.1186/s12957-022-02880-z
pmc: PMC9840315
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6

Informations de copyright

© 2023. The Author(s).

Références

HPB (Oxford). 2011 Jul;13(7):463-72
pubmed: 21689230
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Eur Radiol. 2019 Dec;29(12):6458-6468
pubmed: 31254061
Chin Clin Oncol. 2019 Aug;8(4):37
pubmed: 31431030
Surg Endosc. 2006 May;20(5):721-5
pubmed: 16508808
Ann Surg Oncol. 2003 Mar;10(2):183-9
pubmed: 12620915
Eur J Surg Oncol. 2009 Sep;35(9):903-7
pubmed: 19261430
Ann Surg. 2002 Mar;235(3):392-9
pubmed: 11882761
J Gastrointest Surg. 2007 Sep;11(9):1188-93
pubmed: 17712596
Cancers (Basel). 2020 Apr 09;12(4):
pubmed: 32283627
Surg Clin North Am. 2014 Apr;94(2):343-60
pubmed: 24679425
Nucl Med Commun. 2021 Aug 1;42(8):846-854
pubmed: 33741859
JAMA Surg. 2017 Feb 1;152(2):143-149
pubmed: 27784058
Am Surg. 2017 Jul 1;83(7):679-686
pubmed: 28738935
AJR Am J Roentgenol. 2006 Mar;186(3):758-62
pubmed: 16498103
Ann Surg. 2021 Jan 1;273(1):139-144
pubmed: 30998534
Ann Surg. 2013 Aug;258(2):318-23
pubmed: 23059504
Dig Surg. 2005;22(6):440-5
pubmed: 16479113

Auteurs

Mike van Dooren (M)

Department of Surgery, Radboud university medical center, P.O. Box 9101, Internal Code 618, 6500 HB, Nijmegen, the Netherlands. mike.vandooren@radboudumc.nl.

Elise A J de Savornin Lohman (EAJ)

Department of Surgery, Radboud university medical center, P.O. Box 9101, Internal Code 618, 6500 HB, Nijmegen, the Netherlands.

Eva Brekelmans (E)

Department of Surgery, Radboud university medical center, P.O. Box 9101, Internal Code 618, 6500 HB, Nijmegen, the Netherlands.

Pauline A J Vissers (PAJ)

Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), P.O. Box 19079, 3501 DB, Utrecht, the Netherlands.

Joris I Erdmann (JI)

Department of Surgery, Amsterdam University Medical Centers, P.O. Box 22660, 1100 DD, Amsterdam, the Netherlands.

Andries E Braat (AE)

Department of Surgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, the Netherlands.

Jeroen Hagendoorn (J)

Department of Surgery, UMC Utrecht Cancer Center, P.O. Box 85500, 3508 GA, Utrecht, the Netherlands.
Department of Surgery, St. Antonius Hospital, P.O. Box 2500, 3430 EM, Nieuwegein, the Netherlands.

Freek Daams (F)

Department of Surgery, Amsterdam University Medical Centers, P.O. Box 22660, 1100 DD, Amsterdam, the Netherlands.

Ronald M van Dam (RM)

Department of Surgery, Maastricht University Medical Center +, P.O. Box 5800, 6202 AZ, Maastricht, the Netherlands.

Marieke T de Boer (MT)

Department of Hepatobiliary and Transplant Surgery, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, the Netherlands.

Peter B van den Boezem (PB)

Department of Surgery, Radboud university medical center, P.O. Box 9101, Internal Code 618, 6500 HB, Nijmegen, the Netherlands.

Bas Groot Koerkamp (BG)

Department of Surgery, Erasmus MC, P.O. Box 2060, 3000 CB, Rotterdam, the Netherlands.

Philip R de Reuver (PR)

Department of Surgery, Radboud university medical center, P.O. Box 9101, Internal Code 618, 6500 HB, Nijmegen, the Netherlands. philip.dereuver@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH